Scoping Review of Productivity-Adjusted Life Years (PALYs): Methods, Applications and Policy Implications.

IF 4.6 3区 医学 Q1 ECONOMICS
Zanfina Ademi, Dina Abushanab, Maria J Alfonso Arvez, Clara Marquina, Karl Vivoda, Janne Martikainen, Piia Lavikainen, Melanie Lloyd, Danny Liew
{"title":"Scoping Review of Productivity-Adjusted Life Years (PALYs): Methods, Applications and Policy Implications.","authors":"Zanfina Ademi, Dina Abushanab, Maria J Alfonso Arvez, Clara Marquina, Karl Vivoda, Janne Martikainen, Piia Lavikainen, Melanie Lloyd, Danny Liew","doi":"10.1007/s40273-025-01544-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To understand the application of productivity-adjusted life years (PALYs) as an outcome measure across various disease contexts.</p><p><strong>Methods: </strong>We conducted a scoping review of studies published between 2018 and April 2025 that utilised PALYs to illustrate their potential applications and identify methodological approaches that have been applied. Using a citation-based search, we selected studies that applied PALYs to quantify societal health burdens in specific diseases or contexts. Extracted data included health conditions, country, timeframe, model type, outcomes, productivity index components, gross domestic product and sensitivity analysis. Findings were summarised through narrative synthesis.</p><p><strong>Results: </strong>A total of 41 studies conducted between 2018 and 2025 were reviewed, including chronic diseases such as diabetes and cardiovascular diseases, as well as environmental factors. Conditions such as breast cancer, leukaemia, kidney disease, mental health, knee osteoarthritis, epilepsy and sleep apnoea had the lowest productivity indices. Most of these studies originated from high-income countries (n = 27), followed by upper-middle-income (n = 10), and lower-middle-income (n = 4) settings. Life table models were the most common methodological approach adopted (n = 26), followed by dynamic models (n = 10). Studies focused on disease prevention (n = 21) outnumbered those addressing disease management (n = 18). Most studies accounted for both absenteeism and presenteeism (n = 30). Estimates of productivity loss per person using gross domestic product ranged from US$1137 to AU$217,983 annually.</p><p><strong>Conclusions: </strong>PALYs have been utilised in diverse diseases and contexts, highlighting their utility in measuring societal health impacts. However, adding unpaid and informal work makes burden estimates more accurate. The increasing emphasis on prevention indicates a strategic change in health policy and economic assessment.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40273-025-01544-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To understand the application of productivity-adjusted life years (PALYs) as an outcome measure across various disease contexts.

Methods: We conducted a scoping review of studies published between 2018 and April 2025 that utilised PALYs to illustrate their potential applications and identify methodological approaches that have been applied. Using a citation-based search, we selected studies that applied PALYs to quantify societal health burdens in specific diseases or contexts. Extracted data included health conditions, country, timeframe, model type, outcomes, productivity index components, gross domestic product and sensitivity analysis. Findings were summarised through narrative synthesis.

Results: A total of 41 studies conducted between 2018 and 2025 were reviewed, including chronic diseases such as diabetes and cardiovascular diseases, as well as environmental factors. Conditions such as breast cancer, leukaemia, kidney disease, mental health, knee osteoarthritis, epilepsy and sleep apnoea had the lowest productivity indices. Most of these studies originated from high-income countries (n = 27), followed by upper-middle-income (n = 10), and lower-middle-income (n = 4) settings. Life table models were the most common methodological approach adopted (n = 26), followed by dynamic models (n = 10). Studies focused on disease prevention (n = 21) outnumbered those addressing disease management (n = 18). Most studies accounted for both absenteeism and presenteeism (n = 30). Estimates of productivity loss per person using gross domestic product ranged from US$1137 to AU$217,983 annually.

Conclusions: PALYs have been utilised in diverse diseases and contexts, highlighting their utility in measuring societal health impacts. However, adding unpaid and informal work makes burden estimates more accurate. The increasing emphasis on prevention indicates a strategic change in health policy and economic assessment.

生产力调整生命年(PALYs)的范围审查:方法、应用和政策含义。
目的:了解生产力调整生命年(PALYs)作为不同疾病背景下的结果测量指标的应用。方法:我们对2018年至2025年4月期间发表的研究进行了范围审查,这些研究利用PALYs来说明其潜在应用并确定已应用的方法方法。使用基于引用的搜索,我们选择了应用PALYs量化特定疾病或背景下的社会健康负担的研究。提取的数据包括健康状况、国家、时间框架、模型类型、结果、生产率指数组成部分、国内生产总值和敏感性分析。通过叙述综合总结了调查结果。结果:共回顾了2018年至2025年间开展的41项研究,包括糖尿病、心血管疾病等慢性疾病以及环境因素。乳腺癌、白血病、肾病、精神健康、膝骨关节炎、癫痫和睡眠呼吸暂停等疾病的生产率指数最低。这些研究大多来自高收入国家(n = 27),其次是中高收入国家(n = 10)和中低收入国家(n = 4)。生命表模型是最常用的方法(n = 26),其次是动态模型(n = 10)。关注疾病预防的研究(n = 21)多于关注疾病管理的研究(n = 18)。大多数研究同时考虑了旷工和出勤(n = 30)。按国内生产总值计算,每年人均生产力损失估计在1137美元至217,983澳元之间。结论:PALYs已用于各种疾病和环境,突出了它们在衡量社会健康影响方面的效用。然而,加上无薪和非正式工作使负担估算更加准确。对预防的日益重视表明卫生政策和经济评估的战略变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PharmacoEconomics
PharmacoEconomics 医学-药学
CiteScore
8.10
自引率
9.10%
发文量
85
审稿时长
6-12 weeks
期刊介绍: PharmacoEconomics is the benchmark journal for peer-reviewed, authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes. An invaluable source of applied pharmacoeconomic original research and educational material for the healthcare decision maker. PharmacoEconomics is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization. PharmacoEconomics offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信